A special issue on Nursing: Current Scenario and Future Development - Articles are invited.

Comparative study on efficacy & safety of intravenous iron sucrose versus intramuscular iron sorbitol therapy in anemia during pregnancy

Authors:

Int J Med Res Health Sci. |

Authors: Lomte DB, Bhosale RS, Jambdade V, Gore PR.
Int J Med Res Health Sci. 2013;2(4):719-723 | DOI:10.5958/j.2319-5886.2.4.115

ABSTRACT

Aims and Objectives:  To compare the efficacy, safety, and rate of response of intravenous iron sucrose and intramuscular iron Sorbitol therapy for anemia during pregnancy. Material and Methods: 100 antenatal cases of gestational age 16-32 weeks were included in this prospective study. Cases were randomly divided into two groups. Group A, having 50 cases received intravenous iron sucrose, and 50cases in group B received intramuscular iron sorbitol. Response to therapy in both groups was studied and compared.  Results: The mean pretherapy hemoglobin in group A was 6.49 g/dl and in group B was 6.48 g/dl. The rise in hemoglobin after 4 weeks of starting therapy was 3.52 g/dl in group A and 2.33 g/dl in group B The difference was Statistically significant (P<0.01) The mean time taken to achieve target hemoglobin (>11 g/dl) was 6.37 weeks in group A and 9.04 weeks in group B. In group A, 8% (four) cases had grade I adverse effects. In group B, 24% (12) cases had grade I adverse effects. The difference was statistically significant (P=0.027). In both the groups no case discontinued the therapy. Conclusion:  Intravenous iron sucrose is safe, convenient, more effective, and faster acting therapy than intramuscular iron sorbitol therapy for treating moderate to severe anemia during pregnancy.

Keywords: Iron sucrose, Iron sorbitol, Pregnancy, Iron deficiency.

International Journal of Medical Research & Health Sciences © 2012-16 [Last updated: July 2016] by AspiringDigital